NHS
AstraZeneca’s wins major drug approval by NICE
October 4, 2016Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso
AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
The power of PrEP
August 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug
Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Celgene’s Otezla approved for NHS use
August 3, 2016Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …
Landmark UK ruling as judge rules PrEP can be funded on NHS
August 2, 2016Manufacturing and Production, Research and Development, Sales and Marketing Judge, NHS, PrEP, UK, available, ruling
A London high court judge has ruled in favour of a challenge brought by the National Aids Trust to allow …
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
NHS looking to offer free healthcare apps, devices from next year
June 20, 2016Medical Communications, Research and Development, Sales and Marketing DigitalHealth, HealthTech, NHS, NICE
The NHS will offer devices and apps for free to help patients manage their health, starting in UK next year.
Google’s DeepMind to apply artificial intelligence technology to NHS in next five years
June 13, 2016Medical Communications, Research and Development, Sales and Marketing DeepMind, NHS, collaboration, google, health tech
Google’s artificial intelligence company DeepMind Technologies wants to apply its machine learning technology to NHS patient data within the next …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
Rare disease treatment advocates criticise NHS delays in commissioning
May 24, 2016Medical Communications, Sales and Marketing NHS, commissioning
Medical professionals are calling on NHS England to speed up access to treatment for patients with a rare genetic disease …
Nice backs Novartis’ lung cancer drug
May 20, 2016NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …
Nice backs GSK’s lupus drug Benlysta
May 11, 2016Research and Development, Sales and Marketing GSK, NHS, NICE, regulation
The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus. The …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
ABPI welcomes recommendations from NHS specialised services report
April 27, 2016Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services
The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …
Latest content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
